Laurion Capital Management’s C4 Therapeutics CCCC Stock Holding History

Laurion Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-535,342	Closed	-$4.37M	–	584
2024 Q1	$4.37M	Buy	+535,342	New	+$4.15M	0.04%	269
2023 Q3	–	Sell	-25,983	Closed	-$71.5K	–	504
2023 Q2	$71.5K	Buy	+25,983	New	+$83.5K	﹤0.01%	546
2022 Q1	–	Sell	-581,028	Closed	-$18.7M	–	554
2021 Q4	$18.7M	Sell	581,028 -81,435	-12%	-$3.22M	0.19%	85
2021 Q3	$29.6M	Sell	662,463 -152,941	-19%	-$6.55M	0.12%	163
2021 Q2	$30.9M	Buy	815,404 +547,399	+204%	+$19.6M	0.17%	117
2021 Q1	$9.91M	Buy	268,005 +158,405	+145%	+$6.3M	0.05%	258
2020 Q4	$3.63M	Buy	+109,600	New	+$3.18M	0.03%	279

Other funds holding CCCC

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Laurion Capital Management's CCCC Position: Q2 2024 in Review

Laurion Capital Management sold out of C4 Therapeutics (CCCC) in Q2 2024, closing a stake of 535,342 shares — an estimated $4.37M sold.

Laurion Capital Management first reported a position in CCCC in Q4 2020 and held it in 7 quarters. The position peaked at $30.9M in Q2 2021. 115 funds tracked by Wall St. Rank hold CCCC as of Q2 2024.

Laurion Capital Management reported no remaining C4 Therapeutics position as of Q2 2024 after selling out during the quarter.
Laurion Capital Management sold 535,342 C4 Therapeutics shares in Q2 2024, an estimated $4.37M.
Laurion Capital Management first reported a position in C4 Therapeutics in Q4 2020 and held it in 7 quarters.
Laurion Capital Management's C4 Therapeutics position peaked at $30.9M in Q2 2021.
115 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2024.

Based on Laurion Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.